Patients in England suffering from severe beta-thalassaemia will soon have access to a groundbreaking one-time gene therapy,...

New Systemic Treatment Option Recommended for Patients Aged 12 and Over The National Institute for Health and Care Excellence (NICE) has...

Innovative Oral Therapy Approved for Over 40,000 Patients The National Institute for Health and Care Excellence (NICE) in the UK has...

CSL Behring's Hemgenix has been recommended for managed access as a treatment option for adults with moderately severe or severe...

Keytruda (pembrolizumab) combined with trastuzumab, fluoropyrimidine, and platinum-based chemotherapy is not recommended for initial...

Ivosidenib Plus Azacitidine Endorsed by NICE for Treating Acute Myeloid Leukaemia in Adults Ineligible for Standard Induction...

Aquipta, recommended by NICE, presents a new option for preventing migraines in adults with at least 4 migraine days monthly after at...

NICE announced that artificial intelligence (AI)-derived solutions are available for implementation within the NHS as further evidence is...

January 10, 2024 NICE recommended Alexion's Kanuma for LAL deficiency Sebelipase alfa, marketed as Kanuma by Alexion, holds an indication...

Camzyos (mavacamten) has been recommended as a viable option for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in...

Yescarta has been recommended for adults with diffuse large B-cell lymphoma (DLBCL) after one treatment and is currently indicated as the...

December 15, 2022 SOBI's Doptelet was recommended for treating refractory primary chronic immune thrombocytopenia. NICE recommended using...